Sign in

BIOE on OTC

Bio Essence Corp

Bio Essence Corp is an American pharmaceutical preparations company, incorporated in California.1 It is headquartered in Irvine, California.1 Its shares trade on OTC under the symbol BIOE.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Decoy Therapeutics Inc., Lipocine Inc. or Oramed Pharmaceuticals, or pick any stock.

  • TickerBIOE on OTC1
  • IndustryPharmaceutical Preparations1
  • HeadquartersIrvine, California1
  • Incorporated inCA2
  • Business address2955 Main Street, Ste 300, Irvine, Ca 926142
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

75.3%Gross margin3
47.4%Operating margin3
47.2%Net margin3
485.8%Revenue growth, 20253

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Revenue From OEMServices brought in 100% of the revenue Bio Essence Corp broke down this way in fiscal 2025.

  1. Revenue From OEMServices$1.9M3100%up 571% from 2024
  2. Shipping And Delivery Income$1.2K30%down 68% from 2024
Products and services by year
Products and services20242025
Revenue From OEMServices$282.8K$1.9M
Shipping And Delivery Income$3.8K$1.2K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue25¢$469.2K
  • Other costs28¢$531.4K
  • Income tax0¢$800
  • Profit47¢$896.2K

Out of $1.9M in revenue.3

Where each dollar of operating cash went, fiscal 2025

  • Kept or used elsewhere100¢$1.6M

Out of $1.6M of cash from operations.3

Financial statements

Revenue4563$1.9M in 2025+98% since 2020
0$500.0K$1.0M$1.5M$2.0M2020: $958.7K$958.7K20202021: $888.0K$888.0K2021−7%2022: $621.6K$621.6K2022−30%2023: $551.5K$551.5K2023−11%2024: $323.9K$323.9K2024−41%2025: $1.9M$1.9M2025+486%
Gross profit4563$1.4M in 2025+528% since 2020
0$500.0K$1.0M$1.5M2020: $227.3K$227.3K20202021: $298.3K$298.3K2021+31%2022: $328.3K$328.3K2022+10%2023: $277.4K$277.4K2023−15%2024: $217.1K$217.1K2024−22%2025: $1.4M$1.4M2025+558%
Operating income45673$900.0K in 2025
-$1.0M-$500.0K0$500.0K$1.0M2020: -$832.6K-$832.6K20202021: -$857.5K-$857.5K2021+3%2022: -$511.1K-$511.1K2022−40%2023: -$345.6K-$345.6K2023−32%2024: -$459.4K-$459.4K2024+33%2025: $900.0K$900.0K2025
Net income45673$896.2K in 2025
-$2.0M-$1.0M0$1.0M2020: -$595.8K-$595.8K20202021: -$647.6K-$647.6K2021+9%2022: -$809.7K-$809.7K2022+25%2023: -$971.9K-$971.9K2023+20%2024: -$1.3M-$1.3M2024+35%2025: $896.2K$896.2K2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Total revenues$1.9M$323.9K
Total cost of revenues$469.2K$106.9K
Gross profit$1.4M$217.1K
Selling$30.6K
General and administrative$497.8K$676.5K
Total operating expenses$528.4K$676.5K
Income (loss) from operations$900.0K-$459.4K
Impairment loss of ROU asset-$1.1M
Interest expense-$2.2K-$2.2K
Other income$701
Other expenses-$828-$53.1K
Other expenses, net-$3.0K-$1.1M
Income (loss) before income tax$897.0K-$1.6M
Income tax expense$800$800
Net income (loss) from continuing operations$896.2K-$1.6M
Loss from discontinued operations-$120.8K
Gain from disposal of discontinued operations$377.8K
Net income (loss)$896.2K-$1.3M
Basic weighted average shares outstanding (in Shares)38.0M shares38.0M shares
Diluted weighted average shares outstanding (in Shares)38.0M shares38.0M shares
Basic net loss per share (in Dollars per share)$0-$0
Diluted net loss per share (in Dollars per share)$0-$0

Compare Bio Essence Corp with another company

What it owns

What Bio Essence Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$56.5K7 Dec 31, 2024$60.1K7 Dec 31, 2023−6.0%
Accumulated depreciation$56.5K7 Dec 31, 2024$56.4K7 Dec 31, 2023+0.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.4K7 Dec 31, 2024$1146 Dec 31, 2023+1102.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$973 Dec 31, 2025$3323 Dec 31, 2024−70.8%
Finite-lived intangibles, gross$39.3K3 Dec 31, 2025$39.3K3 Dec 31, 20240%
Accumulated amortization$39.2K3 Dec 31, 2025$38.9K3 Dec 31, 2024+0.6%
Finite-lived intangibles, net$973 Dec 31, 2025$3323 Dec 31, 2024−70.8%

Properties, in its own words

The Company maintains an office at 2955 Main Street, Suite 300, Irvine, CA 92618. This location serves as the Company’s main headquarters. We do not own any properties. We currently have no policy with respect to investments or interests in real estate, real estate mortgages or securities of, or interests in, persons primarily engaged in real estate activities.

Item 2 of the 10-K filed Mar 27, 2026.10

Leadership

Who has led Bio Essence Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Yin Yan2024
2025
  • Chief executive officerYin Yan Jun 3, 2024 to Nov 18, 202411
Board members and other officers (1)
  • Board memberYin Yan Jun 3, 2024 to Nov 18, 202411

Timeline

  1. May 19, 20268-K Entered a material agreement12
  2. Apr 24, 20268-K Entered a material agreement13
  3. Oct 7, 20248-K Earlier financial statements no longer reliable14
  4. Aug 9, 20248-K Change of auditor15
  5. Aug 5, 20248-K Change of auditor16
  6. Jun 21, 20248-K Executive or director change; Other events17
  7. Jun 3, 2024New chief executive Yin Yan becomes CEO11
  8. Apr 4, 20248-K Entered a material agreement18
  9. Dec 13, 20238-K Entered a material agreement; Executive or director change19
  10. Sep 7, 20238-K Executive or director change20
  11. Jun 6, 20238-K Other events21

Filings

58 filings to the SEC since October 2021: 5 annual reports, 21 quarterly reports, 10 major events, 8 insider forms, 14 other. The latest 20:

  1. Oct 14, 20264/A EDGAR
  2. Oct 13, 2026144 EDGAR
  3. Aug 14, 202610-Q QUARTERLY REPORT EDGAR
  4. May 19, 20268-K/A AMENDMENT NO. 1 TO FORM 8-K EDGAR
  5. May 15, 202610-Q QUARTERLY REPORT EDGAR
  6. Apr 24, 20268-K CURRENT REPORT EDGAR
  7. Mar 27, 202610-K ANNUAL REPORT EDGAR
  8. Jan 5, 2026QUALIF EDGAR
  9. Nov 12, 202510-Q QUARTERLY REPORT EDGAR
  10. Oct 17, 20251-A EDGAR
  11. Aug 14, 202510-Q QUARTERLY REPORT EDGAR
  12. May 15, 202510-Q QUARTERLY REPORT EDGAR
  13. Mar 28, 202510-K ANNUAL REPORT EDGAR
  14. Dec 5, 2024UPLOAD EDGAR
  15. Nov 27, 202410-Q/A AMENDMENT NO. 3 TO FORM 10-Q EDGAR
  16. Nov 27, 202410-Q/A AMENDMENT NO. 3 TO FORM 10-Q EDGAR
  17. Nov 18, 20244 EDGAR
  18. Nov 14, 202410-Q QUARTERLY REPORT EDGAR
  19. Nov 8, 2024UPLOAD EDGAR
  20. Oct 30, 202410-Q/A AMENDMENT NO. 2 TO FORM 10-Q EDGAR

The 58 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

15 open-market trades by officers, directors and large owners since October 2021: 2 buys and 13 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 30, 2024Yan YinChief Executive OfficerSale143,845$0.57$82.0KForm 4
Oct 29, 2024Yan YinChief Executive OfficerSale40,000$0.64$25.6KForm 4
Oct 28, 2024Yan YinChief Executive OfficerSale140,000$2.48$347.2KForm 4
Sep 30, 2024Yan YinChief Executive OfficerSale1,990$2.35$4.7KForm 4
Sep 27, 2024Yan YinChief Executive OfficerSale200$1.69$338Form 4
Sep 26, 2024Yan YinChief Executive OfficerSale40,000$1.67$66.8KForm 4
Sep 25, 2024Yan YinChief Executive OfficerSale50,000$0.70$35.0KForm 4
Jul 5, 2024Yan YinChief Executive OfficerSale73,965$8.94$661.2KForm 4
Jul 5, 2024Yan YinChief Executive OfficerSale6,209$9.07$56.3KForm 4
Jul 3, 2024Yan YinChief Executive OfficerSale100,000$8.78$878.0KForm 4
Jul 3, 2024Yan YinChief Executive OfficerSale4,065$8.96$36.4KForm 4
Jul 2, 2024Yan YinChief Executive OfficerSale50,000$7.83$391.5KForm 4
Jul 2, 2024Yan YinChief Executive OfficerSale50,000$7.83$391.5KForm 4
Jun 6, 2023Yan YinChief Executive OfficerBuy5,000,000$0.50$2.5MForm 4
Jun 6, 2023Yan YinChief Executive OfficerBuy5,000,000$0.50$2.5MForm 4

From Forms 4 filed with the SEC.

SEC filer profile

How Bio Essence Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBio Essence Corp1
  • CIK0001723059
  • Employer ID (EIN)94-334955110
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company10
  • Incorporated inCalifornia10
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address2955 Main Street, Ste 300, Irvine, CA 926141
  • Phone888-816-14941
  • Shares outstanding53,809,000 as of Aug 14, 20269
  • Public float$26.8M as of Dec 31, 202510
  • AuditorSimon & Edward, LLP, Rowland Heights, CA PCAOB ID 2485; no auditor attestation of internal control over financial reporting10
  • On EDGAR sinceNov 16, 20171
  • Filings85 in all: 10-Q (17), 8-K (9), UPLOAD (9), 10-K (6), 10-Q/A (6), S-1/A (6), 4 (4), CORRESP (4)1
    All 23 form types

    144 (3), 4/A (3), NT 10-Q (3), 8-K/A (2), D (2), NT 10-K (2), 1-A (1), 144/A (1), 3 (1), 8-A12G (1), D/A (1), DEL AM (1), EFFECT (1), QUALIF (1), S-1 (1)

  • Latest filingsAnnual report (10-K) Mar 27, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Latest 8-K (8-K) Apr 24, 2026

Risk factors and legal proceedings

Legal proceedings

On or about February 27, 2026, Stason Industrial Corporation (“SIC”) and Stason Pharmaceuticals, Inc. (“SPI,” collectively “Stason”) filed a Complaint in the Superior Court of Orange County, in California (the “Complaint”), alleging that the Company breached its contract and lease obligations relating to a large commercial space previously utilized by the Company. The Company and ten (10) unidentified individuals are defendants of the case. The Complaint alleges that the Company (1) breached rental payment obligations, and accrued late fees and other penalties pursuant to the operative agreements, and (2) breached a separate contract whereby the Company allegedly failed to perform certain laboratory and pharmaceutical processing services. The Complaint seeks $1,504,823.81 in damages as of January of 2026, relating to unpaid rent, lost revenue, and other damages. The Company denies the allegations and is in the process of retaining legal counsel. The Company intends on bringing counterclaims and affirmative defenses relating to first material breaches committed by Stason.

The opening of Item 3, Legal Proceedings.10

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
    SEC EDGAROther events